Turn Therapeutics Inc.

Turn Therapeutics Inc. is a biotechnology and pharmaceuticals company dedicated to developing innovative drugs and medical devices for dermatological, wound care, and infectious disease management. Central to its approach is the proprietary PermaFusion drug delivery platform, which enables the stable suspension of water-soluble active pharmaceutical ingredients within oil-based carriers, enhancing bioavailability and reducing the risk of adverse effects tied to lower active ingredient dosages. Founded in 2015 and headquartered in Westlake Village, California, the company focuses primarily on diseases of the skin, nails, and eyes, with significant research and clinical programs addressing moderate to severe eczema and onychomycosis (nail fungus). Turn Therapeutics' technologies, including its flagship Hexagen formula, have achieved multiple FDA medical device clearances for advanced wound and dermatitis care, substantiating their safety and efficacy. The company’s mission centers on advancing patient-centric therapies that minimize invasiveness and antibiotic resistance, respond to unmet medical needs, and continuously redefine standards of care in the healthcare and biotechnology sectors.